B. Scott Ullem's most recent trade in Illumina Inc was a trade of 3,780 Common Stock done . Disclosure was reported to the exchange on May 21, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 May 2025 | 3,780 | 7,830 (0%) | 0% | 0 | Common Stock | |
| Illumina Inc | Scott B. Ullem | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 83.62 per share. | 16 May 2025 | 1,070 | 4,050 (0%) | 0% | 83.6 | 89,473 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 73.68 per share. | 11 May 2025 | 1,200 | 39,898 (0%) | 0% | 73.7 | 88,416 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 75,200 | 75,200 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 13,400 | 13,400 | - | - | Performance Rights | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2025 | 13,400 | 41,098 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2025 | 11,250 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 74.40 per share. | 07 May 2025 | 11,250 | 41,098 (0%) | 0% | 74.4 | 837,035 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 07 May 2025 | 11,250 | 52,348 (0%) | 0% | 45.3 | 509,363 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 74.92 per share. | 07 May 2025 | 1,406 | 27,698 (0%) | 0% | 74.9 | 105,338 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.65 per share. | 03 May 2025 | 648 | 29,104 (0%) | 0% | 75.6 | 49,021 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 75.65 per share. | 03 May 2025 | 635 | 29,752 (0%) | 0% | 75.7 | 48,038 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 104.92 per share. | 31 Mar 2025 | 229 | 5,120 (0%) | 0% | 104.9 | 24,027 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 26 Mar 2025 | 11,250 | 11,250 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.87 per share. | 26 Mar 2025 | 11,250 | 30,387 (0%) | 0% | 70.9 | 797,267 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 26 Mar 2025 | 11,250 | 41,637 (0%) | 0% | 45.3 | 509,363 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 11,250 | 22,500 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 28 Feb 2025 | 11,250 | 41,637 (0%) | 0% | 45.3 | 509,363 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 70.52 per share. | 28 Feb 2025 | 7,760 | 30,387 (0%) | 0% | 70.5 | 547,204 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.38 per share. | 28 Feb 2025 | 3,490 | 38,147 (0%) | 0% | 71.4 | 249,123 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 76.19 per share. | 16 Feb 2025 | 174 | 30,387 (0%) | 0% | 76.2 | 13,257 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 75.76 per share. | 13 Feb 2025 | 11,250 | 30,561 (0%) | 0% | 75.8 | 852,272 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 13 Feb 2025 | 11,250 | 41,811 (0%) | 0% | 45.3 | 509,363 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 11,250 | 33,750 | - | - | Employee Stock Option (Right to Acquire) | |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 142.06 per share. | 31 Dec 2024 | 158 | 4,891 (0%) | 0% | 142.1 | 22,446 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 09 Dec 2024 | 11,250 | 41,811 (0%) | 0% | 45.3 | 509,363 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Dec 2024 | 11,250 | 45,000 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 71.68 per share. | 09 Dec 2024 | 11,250 | 30,561 (0%) | 0% | 71.7 | 806,406 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 122.78 per share. | 30 Sep 2024 | 183 | 4,733 (0%) | 0% | 122.8 | 22,469 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 109.65 per share. | 28 Jun 2024 | 205 | 4,550 (0%) | 0% | 109.7 | 22,479 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 20 Jun 2024 | 5,625 | 36,186 (0%) | 0% | 45.3 | 254,681 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 20 Jun 2024 | 5,625 | 56,250 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 87.47 per share. | 20 Jun 2024 | 5,225 | 30,561 (0%) | 0% | 87.5 | 457,013 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.11 per share. | 20 Jun 2024 | 400 | 35,786 (0%) | 0% | 88.1 | 35,245 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 90.45 per share. | 21 May 2024 | 5,625 | 30,561 (0%) | 0% | 90.5 | 508,803 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 21 May 2024 | 5,625 | 61,875 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 45.28 per share. | 21 May 2024 | 5,625 | 36,186 (0%) | 0% | 45.3 | 254,681 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 May 2024 | 2,622 | 4,292 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.72 per share. | 11 May 2024 | 1,198 | 30,561 (0%) | 0% | 86.7 | 103,891 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 65,500 | 65,500 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 11,075 | 32,549 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 11,075 | 11,075 | - | - | Performance Rights | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.09 per share. | 07 May 2024 | 790 | 31,759 (0%) | 0% | 85.1 | 67,221 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 7,465 | 25,905 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 May 2024 | 7,465 | 0 | - | - | Performance Rights | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.25 per share. | 03 May 2024 | 4,431 | 21,474 (0%) | 0% | 85.3 | 377,743 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 85.06 per share. | 03 May 2024 | 634 | 18,440 (0%) | 0% | 85.1 | 53,928 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 30 Apr 2024 | 7,250 | 26,324 (0%) | 0% | 36.8 | 266,438 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 7,250 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.74 per share. | 30 Apr 2024 | 6,550 | 19,074 (0%) | 0% | 85.7 | 561,579 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 86.40 per share. | 30 Apr 2024 | 700 | 25,624 (0%) | 0% | 86.4 | 60,483 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 01 Apr 2024 | 7,255 | 26,329 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2024 | 7,255 | 7,250 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 94.81 per share. | 01 Apr 2024 | 6,387 | 19,074 (0%) | 0% | 94.8 | 605,521 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 95.51 per share. | 01 Apr 2024 | 868 | 25,461 (0%) | 0% | 95.5 | 82,903 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 137.68 per share. | 28 Mar 2024 | 163 | 1,670 (0%) | 0% | 137.7 | 22,442 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Feb 2024 | 7,255 | 14,505 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | B. Scott Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 85.59 per share. | 29 Feb 2024 | 7,255 | 19,074 (0%) | 0% | 85.6 | 620,923 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 29 Feb 2024 | 7,255 | 26,329 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Ullem B. Scott | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 86.04 per share. | 16 Feb 2024 | 174 | 19,074 (0%) | 0% | 86.0 | 14,971 | Common Stock |
| Edwards Lifesciences Corp | B. Ullem Scott | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 01 Feb 2024 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Ullem B. Scott | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2024 | 7,255 | 21,760 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott Ullem B. | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 78.29 per share. | 01 Feb 2024 | 7,255 | 19,248 (0%) | 0% | 78.3 | 567,994 | Common Stock |
| Edwards Lifesciences Corp | B. Ullem Scott | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 29 Dec 2023 | 14,510 | 33,758 (0%) | 0% | 36.8 | 533,243 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 76.55 per share. | 29 Dec 2023 | 14,510 | 19,248 (0%) | 0% | 76.6 | 1,110,794 | Common Stock |
| Edwards Lifesciences Corp | Ullem Scott B. | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Dec 2023 | 14,510 | 29,015 | - | - | Employee Stock Option (Right to Acquire) | |
| Berry Global Group Inc | Scott B. Ullem | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2023 | 1,970 | 1,393 | - | - | Restricted Stock Units | |
| Berry Global Group Inc | Scott B. Ullem | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 25 Nov 2023 | 1,970 | 4,728 (0%) | 0% | - | Common Stock | |
| Berry Global Group Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 2,823 | 57,235 | - | - | Director Stock Option (Right to Buy) | |
| Berry Global Group Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Nov 2023 | 1,393 | 3,363 | - | - | Restricted Stock Units | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Oct 2023 | 7,255 | 43,525 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 31 Oct 2023 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 62.66 per share. | 31 Oct 2023 | 7,255 | 19,248 (0%) | 0% | 62.7 | 454,569 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 69.54 per share. | 29 Sep 2023 | 7,255 | 19,248 (0%) | 0% | 69.5 | 504,527 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 29 Sep 2023 | 7,255 | 50,780 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 29 Sep 2023 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Aug 2023 | 7,255 | 58,035 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 31 Aug 2023 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 77.79 per share. | 31 Aug 2023 | 7,255 | 19,248 (0%) | 0% | 77.8 | 564,366 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 84.35 per share. | 31 Jul 2023 | 7,255 | 19,248 (0%) | 0% | 84.3 | 611,959 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 31 Jul 2023 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jul 2023 | 7,255 | 65,290 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 93.27 per share. | 30 Jun 2023 | 7,255 | 19,248 (0%) | 0% | 93.3 | 676,674 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jun 2023 | 7,255 | 72,545 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 36.75 per share. | 30 Jun 2023 | 7,255 | 26,503 (0%) | 0% | 36.7 | 266,621 | Common Stock |
| Illumina Inc | Scott B. Ullem | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2023 | 1,507 | 1,507 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 8,496 | 266,318 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Gift of securities by or to the insider at price $ 0.00 per share. | 17 May 2023 | 8,496 | 19,248 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 72,900 | 72,900 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 11,825 | 11,825 | - | - | Performance Rights | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 May 2023 | 9,450 | 27,744 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 May 2023 | 80,700 | 0 | - | - | Employee Stock Option (Right to Acquire) | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 35.20 per share. | 10 May 2023 | 80,700 | 98,994 (0%) | 0% | 35.2 | 2,840,374 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 88.36 per share. | 10 May 2023 | 64,119 | 18,294 (0%) | 0% | 88.4 | 5,665,619 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 89.22 per share. | 10 May 2023 | 16,581 | 82,413 (0%) | 0% | 89.2 | 1,479,385 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 6,062 | 1,663 | - | - | Performance Rights | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 07 May 2023 | 6,062 | 22,972 (0%) | 0% | 0 | Common Stock | |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.74 per share. | 07 May 2023 | 3,004 | 19,968 (0%) | 0% | 88.7 | 266,575 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.74 per share. | 07 May 2023 | 1,674 | 18,294 (0%) | 0% | 88.7 | 148,551 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 88.10 per share. | 03 May 2023 | 441 | 16,910 (0%) | 0% | 88.1 | 38,852 | Common Stock |
| Edwards Lifesciences Corp | Scott B. Ullem | CVP, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 87.81 per share. | 03 May 2023 | 433 | 17,351 (0%) | 0% | 87.8 | 38,022 | Common Stock |